Fullscript Inc., the Ottawa-based healthcare technology platform that enables practitioners to deliver whole-person care through evidence-based supplement prescribing and fulfillment, advanced lab management, and patient adherence tools, has been the subject of an ongoing series of growth equity transactions since September 2021, aggregating approximately US$215 million in committed capital led by HGGC, Snapdragon Capital Partners, and most recently Leonard Green & Partners. HGGC, a Palo Alto-based middle-market private equity firm, originally invested in Fullscript in 2021 with Snapdragon Capital Partners as a minority co-investor. On May 5, 2025, Fullscript announced an expanded investment from HGGC and Snapdragon, supported by a continuation vehicle in which Leonard Green & Partners acted as sole lead investor. Kirkland & Ellis publicly described the 2025 transaction as a single-asset, general-partner-led secondary structured to deliver a bespoke liquidity solution to existing Snapdragon investors while channeling additional primary capital into Fullscript to support its next phase of growth. The transaction was negotiated bilaterally and without a financial advisor. Fullscript today supports more than 100,000 healthcare providers and approximately 10 million patients, with its platform operating across both Canada and the United States and recent strategic acquisitions including Rupa Health and Emerson Ecologics. Kyle Braatz, Co-Founder and Chief Executive Officer of Fullscript, framed the expanded financing as a vote of confidence in the company's integrative-care model and long-term market leadership.